Detalhe da pesquisa
1.
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease.
Ther Drug Monit
; 39(4): 344-349, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28328760
2.
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
J Clin Gastroenterol
; 49(1): 34-40, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25485513
3.
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
Dig Dis Sci
; 60(10): 3075-84, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26044830
4.
HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients.
Inflamm Bowel Dis
; 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38029420
5.
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study.
Inflamm Bowel Dis
; 23(10): 1840-1846, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28644182